May 2024
Core topics in this month’s edition include:
- Halaven (eribulin) – first time generic
- Opuviz (aflibercept-yszy) – new first-time interchangeable biosimilar approval
- Simlandi (adalimumab-ryvk) – interchangeable biosimilar approval
- Yesafili (aflibercept-jbvf) - new first-time interchangeable biosimilar approval